Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  McKesson Corporation    MCK

MCKESSON CORPORATION

(MCK)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

McKesson : Pemazyre (pemigatinib) Available Exclusively at Biologics by McKesson

share with twitter share with LinkedIn share with facebook
05/27/2020 | 01:13pm EDT

CARY, N.C., May 27, 2020-Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, will be the exclusive specialty pharmacy provider for Pemazyre™ (pemigatinib), Incyte's selective fibroblast growth factor receptor (FGFR) inhibitor, recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test. For more information on Pemazyre, please visit www.pemazyre.com.

'Biologics is pleased to exclusively dispense this new therapy to patients who need an alternative to chemotherapy,' said Brandon Tom, vice president of Commercial Services, Biologics by McKesson. 'As a single source for helping biopharma companies provide high-quality support for patients, we believe we are the perfect partner for those whose therapies treat complex patient populations in need of high-touch care.'

Biologics specialty pharmacy is committed to and recognized for its level of customer service as well as its innovative, high-touch and multidisciplinary patient-centric approach. Each team includes pharmacists with in-depth knowledge of therapies, experienced nurses, and financial counselors who are familiar with various financial assistance programs and organizations that help patients. This deeply skilled care team works together to develop individualized care plans that address each patient's unique clinical, financial and emotional needs and streamlines communication back to the treating provider, enabling high-quality care and differentiated outcomes. In addition, the Biologics team works closely with payers to ensure patients can access the specialty medications they need.

Physicians may submit prescriptions to Biologics via phone (800.850.4306), fax (800.823.4506) or eScribe. For electronic prescribing systems, physicians may search for Biologics within their EMR system.

Pemazyre™ is a trademark of Incyte.

About Biologics by McKesson

Biologics by McKesson is an independent specialty pharmacy with more than 25 years of experience connecting patients to life-changing medications in oncology and other rare and complex therapeutic areas. Built on the foundation of deep clinical expertise and a high-touch approach to patient care, Biologics delivers seamless access and personalized engagement, so patients get the most out of the care they receive. As part of McKesson Life Sciences, a business within McKesson Corporation, Biologics harnesses unparalleled reach and connectivity across the healthcare system to connect the dots between payers, providers and biopharma, so together, they can deliver better care and outcomes for every patient.

PR Contact

Claire Crye
Public Relations
281-825-9927
Claire.Crye@McKesson.com



CARY, N.C., May 27, 2020-Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, will be the exclusive specialty pharmacy provider for Pemazyre™ (pemigatinib), Incyte's selective fibroblast growth factor receptor (FGFR) inhibitor, recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test. For more information on Pemazyre, please visit www.pemazyre.com.

'Biologics is pleased to exclusively dispense this new therapy to patients who need an alternative to chemotherapy,' said Brandon Tom, vice president of Commercial Services, Biologics by McKesson. 'As a single source for helping biopharma companies provide high-quality support for patients, we believe we are the perfect partner for those whose therapies treat complex patient populations in need of high-touch care.'

Biologics specialty pharmacy is committed to and recognized for its level of customer service as well as its innovative, high-touch and multidisciplinary patient-centric approach. Each team includes pharmacists with in-depth knowledge of therapies, experienced nurses, and financial counselors who are familiar with various financial assistance programs and organizations that help patients. This deeply skilled care team works together to develop individualized care plans that address each patient's unique clinical, financial and emotional needs and streamlines communication back to the treating provider, enabling high-quality care and differentiated outcomes. In addition, the Biologics team works closely with payers to ensure patients can access the specialty medications they need.

Physicians may submit prescriptions to Biologics via phone (800.850.4306), fax (800.823.4506) or eScribe. For electronic prescribing systems, physicians may search for Biologics within their EMR system.

Pemazyre™ is a trademark of Incyte.

About Biologics by McKesson

Biologics by McKesson is an independent specialty pharmacy with more than 25 years of experience connecting patients to life-changing medications in oncology and other rare and complex therapeutic areas. Built on the foundation of deep clinical expertise and a high-touch approach to patient care, Biologics delivers seamless access and personalized engagement, so patients get the most out of the care they receive. As part of McKesson Life Sciences, a business within McKesson Corporation, Biologics harnesses unparalleled reach and connectivity across the healthcare system to connect the dots between payers, providers and biopharma, so together, they can deliver better care and outcomes for every patient.

PR Contact

Claire Crye
Public Relations
281-825-9927
Claire.Crye@McKesson.com



Disclaimer

McKesson Corporation published this content on 27 May 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 27 May 2020 17:12:02 UTC

share with twitter share with LinkedIn share with facebook
Latest news on MCKESSON CORPORATION
07/06MCKESSON CORPORATION : to Announce First Quarter Fiscal 2021 Results on August 3..
BU
07/01MCKESSON : Changes Business-Unit Structure
DJ
07/01MCKESSON CORP : Regulation FD Disclosure, Financial Statements and Exhibits (for..
AQ
07/01MCKESSON : Realigns Organizational Structure to Better Serve Customers and Patie..
BU
06/30KARYOPHARM THERAPEUTICS : XPOVIO, FDA Approved for Treatment of Relapsed or Refr..
AQ
06/29MCKESSON : XPOVIO (selinexor), FDA Approved for Treatment of Relapsed or Refract..
PU
06/19MCKESSON : Partners with Walmart to Deliver nearly 10 million Critical Medical G..
PU
06/05MCKESSON : Appoints Tom Rodgers to Executive Vice President and Chief Strategy a..
AQ
06/04MCKESSON : Appoints Tom Rodgers to Executive Vice President & Chief Strategy and..
BU
06/03ELI LILLY AND : RETEVMO, FDA-Approved for Treatment of RET-driven Lung and Thyro..
AQ
More news
Financials (USD)
Sales 2021 236 B - -
Net income 2021 1 870 M - -
Net Debt 2021 2 045 M - -
P/E ratio 2021 12,4x
Yield 2021 1,20%
Capitalization 23 186 M 23 186 M -
EV / Sales 2020
EV / Sales 2021 0,11x
Nbr of Employees 70 000
Free-Float 59,5%
Chart MCKESSON CORPORATION
Duration : Period :
McKesson Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MCKESSON CORPORATION
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Average target price 170,59 $
Last Close Price 143,02 $
Spread / Highest target 35,6%
Spread / Average Target 19,3%
Spread / Lowest Target 2,78%
EPS Revisions
Managers
NameTitle
Brian Scott Tyler Chief Executive Officer & Director
Edward A. Mueller Chairman
Britt Vitalone Chief Financial Officer & Executive Vice President
Nancy Flores EVP, Chief Technology & Information Officer
M. Christine Jacobs Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
MCKESSON CORPORATION3.40%23 186
WALGREENS BOOTS ALLIANCE, INC.-33.84%34 765
CARDINAL HEALTH, INC.-3.36%14 412
WELCIA HOLDINGS CO., LTD.26.62%8 609
SINOPHARM GROUP CO., LTD.-30.69%7 935
HUADONG MEDICINE CO., LTD18.05%7 194